Brief: Moleculin Biotech Receives Nasdaq Deficiency Letter For Bid Price - SEC Filing
27/06/2025 22:14
June 27 (Reuters) - Moleculin Biotech Inc MBRX.O: MOLECULIN BIOTECH INC - RECEIVES NASDAQ DEFICIENCY LETTER FOR BID PRICE - SEC FILING Source text: [ID:n0001437749-25-021445] Further company coverage: MBRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM